Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Siemens Medical Solutions Diagnostics and KreLo agree to develop TRAb assay

Siemens Healthcare Diagnostics UK : 18 December, 2007  (New Product)
Siemens Medical Solutions Diagnostics has signed an agreement with KreLo Medical Diagnostics for the rights to develop an automated stimulating TSH receptor antibody (TRAb) assay used in the differential diagnosis of Graves' disease.
The agreement will make Siemens Medical Solutions Diagnostics the first in vitro diagnostics distributor of an automated TRAb Assay featuring stimulating TRAb KreLo antibodies which are specific to the diagnosis of Graves' disease.

'The new TRAb Assay has enormous potential to help diagnose, monitor and predict the course of Graves' disease,' said Joe Bernardo, senior vice president, Central Lab Testing, Siemens Medical Solutions Diagnostics. 'Siemens continues to focus on new Biomarker development opportunities, continually expanding our already comprehensive immunoassay menu and providing the diagnostic tools necessary to diagnose and treat millions of thyroid disease patients.'

Graves' disease affects approximately 32 million people worldwide. As one of the most common form of hyperthyroidism, Graves' is an autoimmune disorder characterized by the presence of stimulating TSH receptor autoantibodies found approximately 90 percent of Graves' patients. TSH receptor autoantibodies mimic the activity of TSH, leading to an elevated production of thyroid hormone. Left untreated, Graves' disease can lead to miscarriage, birth defects, thyroid eye disease and can be life-threatening.

Studies have shown that the TRAb test has the highest diagnostic power to differentiate Graves' disease from toxic nodular goiters. KreLo focuses on research and development of diagnostic kits for application in human medicine. The company was co-founded by Werner Kress and Prof Ulrich Loos, formerly professor at the Department of Medicine at Ulm University (Ulm, Germany). Prof Loos is the CEO of KreLo.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo